Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tristel ups dividend as first-half profits jump

(Sharecast News) - Disinfectants manufacturer Tristel raised its interim dividend by 8% after a double-digit increase in profits in its first half, though sales growth in the UK has slowed dramatically. The company, whose products contain proprietary chlorine dioxide technology, reported an adjusted pre-tax profit of £4.9m for the six months to 31 December, up 19% on the year before. The adjusted pre-tax profit margin improved to 21% from 20%.

Revenues were 8% higher at £22.6m, with UK sales up 7% at £8.8m and overseas sales rising 9% to £13.8m.

Following a 31% surge in UK sales in the last financial year ended 30 June 2024, chief executive Matt Sassone said Tristel's largest market "has now returned to a more typical trading pattern" following an exceptional performance.

Nevertheless, Sassone labelled the first half as a "strong financial performance" for the company, "driven by higher first-half revenues, maintained gross margin, and disciplined cost control".

"As outlined in our AGM statement, we remain on track to meet our internal revenue growth target of 10-15% CAGR over the three years to 30 June 2025," he said.

Tristel declared an interim dividend of 5.68p per share, up from 5.24p paid out last year.

Shares were down 2% at 340p in afternoon trade, extending the year-to-date loss to 20%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.